COMMUNIQUÉS West-GlobeNewswire

Erdem Hospital Launches New Pre-Surgery Education Program for Bariatric Patients
30/06/2025
Photo: Erdem Hospital via FL Communications ISTANBUL, June 30, 2025 (GLOBE NEWSWIRE) -- Erdem Hospital in Istanbul has announced the launch of a new pre-operative education program tailored specifically for bariatric [...]
Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer
30/06/2025
Breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development and diagnostics LONDON, June 30, 2025 (GLOBE NEWSWIRE) -- Portal Biotech, a [...]
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
30/06/2025
– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – – Lorundrostat 50 mg once daily demonstrated clinically [...]
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
30/06/2025
Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Acentra Health Earns Fourth Consecutive Recognition on the Washington Business Journal’s Annual ‘Largest Private Companies’ List
30/06/2025
Strategic investments in its solutions and workforce fuel the company’s consistent growth in WBJ’s rankings, earning the No. 43 spot in 2025 MCLEAN, Va., June 30, 2025 (GLOBE NEWSWIRE) -- Acentra Health , a technology [...]
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
30/06/2025
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Completion of Share Buy-back Program
30/06/2025
Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a [...]
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
30/06/2025
Vancouver, Canada, June 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Senti Bio Participates in Nasdaq Amplify Spotlight Series
30/06/2025
Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next- [...]
GCANRx Announces Uplisting to New Market Tier
30/06/2025
BALTIMORE, June 30, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and [...]
INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute
30/06/2025
MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, is excited to announce [...]
Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis
30/06/2025
The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously reported two [...]
EVA Pharma and Zhejiang Jinhua CONBA Bio-Pharm Sign Strategic Supply Agreement
30/06/2025
Two Regional Powerhouses to Strengthen Cross-Border Collaboration for a More Resilient and Accessible Healthcare Supply Chain SHANGHAI and CAIRO, June 30, 2025 (GLOBE NEWSWIRE) -- EVA Pharma , one of the leading [...]
Clover Health Set to Join Russell 3000® Index
30/06/2025
WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market [...]
Microbot Medical® Added to the Russell Microcap® Index
30/06/2025
Automatic inclusion in the appropriate growth and value style indexes HINGHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic [...]
Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study
30/06/2025
Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with [...]
Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet-AMD at 2025 MaculArt Meeting
30/06/2025
Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD Novel subcutaneous delivery may offer a more patient-friendly alternative to [...]
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation
30/06/2025
SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. [...]
Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement
30/06/2025
Increases total holdings to 1,306,452 HYPE LAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly [...]

Pages